Literature DB >> 9683552

Intranasal administration of denatured type II collagen and its fragments can delay the onset of collagen-induced arthritis.

T Matsumoto1, A Ametani, S Hachimura, A Iwaya, Y Taguchi, K Fujita, T Shigehisa, S Kaminogawa.   

Abstract

Collagen-induced arthritis (CIA) is an autoimmune animal model for some types of human rheumatoid arthritis (RA). We have evaluated the effectiveness of intranasal administration of antigen in inhibiting CIA in DBA/1 mice. The intranasal administration of heat-denatured or trypsin-digested bovine type II collagen (CII) before immunization with CII strongly delayed the onset of CIA, whereas administration of native CII did not do so. The mice administered denatured or digested CII possessed much lower titers of anti-CII IgG2a than the control mice, whereas titers of anti-CII IgG1 and IgG2b were unchanged or slightly decreased. Responding to CII and peptides containing immunodominant T cell determinants, lymph node cells from mice administered denatured CII produced less IFN-gamma. These results suggest that intranasal administration of antigen downregulated preferentially Th1-type responses, whereas an enhanced Th2-type response was not observed. We demonstrate that the methods shown here are a possible treatment for rheumatoid arthritis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683552     DOI: 10.1006/clin.1998.4521

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Serological investigation of IgG levels and subclasses in rheumatoid arthritis patients following ingestion of bovine type II collagen: results of a double blind, randomised controlled trial.

Authors:  Amir Farboud; Ernest Choy
Journal:  Clin Rheumatol       Date:  2010-05-04       Impact factor: 2.980

Review 2.  FLT3 inhibitors for the treatment of autoimmune disease.

Authors:  Katharine A Whartenby; Donald Small; Peter A Calabresi
Journal:  Expert Opin Investig Drugs       Date:  2008-11       Impact factor: 6.206

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.